New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?

New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?

Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in fact increasingly focusing on developing DNA damage repair (DDR) defect-driven no...

Full description

Bibliographic Details
Main Authors:	Gaetano Aurilio, Alessia Cimadamore, Matteo Santoni, Franco Nolè, Marina Scarpelli, Francesco Massari, Antonio Lopez-Beltran, Liang Cheng, Rodolfo Montironi
Format:	Article
Language:	English
Published:	MDPI AG 2020-06-01
Series:	Cells
Subjects:	prostate cancer metastatic castration-resistant prostate cancer DNA damage repair ARS inhibitors PARP inhibitors immune checkpoint inhibitors
Online Access:	https://www.mdpi.com/2073-4409/9/6/1522

Similar Items

The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors
by: А. А. Gritskevich, et al.
Published: (2021-06-01)

Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches
by: Catherine Handy Marshall, et al.
Published: (2020-01-01)

Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations
by: Wu MS, et al.
Published: (2022-11-01)

Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis
by: Brigida Anna Maiorano, et al.
Published: (2025-02-01)

Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer
by: Rodolfo Montironi, et al.
Published: (2020-04-01)

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
by: Gaetano Aurilio, et al.
Published: (2020-12-01)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
by: Sree M. Lanka, et al.
Published: (2023-04-01)

Past, Current, and Future of Immunotherapies for Prostate Cancer
by: Adeline N. Boettcher, et al.
Published: (2019-09-01)

Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer
by: Alessia Cimadamore, et al.
Published: (2020-06-01)

Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
by: Fernando López-Campos, et al.
Published: (2022-02-01)

Use of PARP inhibitors in prostate cancer: from specific to broader application
by: Zhenting Zhang, et al.
Published: (2023-04-01)

Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer
by: Veronica Mollica, et al.
Published: (2019-01-01)

Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
by: Inês Costa, et al.
Published: (2022-05-01)

DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment
by: Jeong Min Lee, et al.
Published: (2025-01-01)

Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
by: Joel Mintz, et al.
Published: (2021-01-01)

Novel therapies are changing treatment paradigms in metastatic prostate cancer
by: Eric Powers, et al.
Published: (2020-10-01)

Prostate cancer and PARP inhibitors: progress and challenges
by: Diego Teyssonneau, et al.
Published: (2021-03-01)

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: Kan Wu, et al.
Published: (2021-12-01)

New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen
by: Alessia Cimadamore, et al.
Published: (2018-12-01)

Defective DNA repair mechanisms in prostate cancer: impact of olaparib
by: De Felice F, et al.
Published: (2017-03-01)

Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis
by: Xiangyu Chen, et al.
Published: (2023-03-01)

PARP Inhibitors: A New Horizon for Patients with Prostate Cancer
by: Belén Congregado, et al.
Published: (2022-06-01)

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
by: Jingsong Zhang
Published: (2014-06-01)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
by: Nizialek E, et al.
Published: (2020-09-01)

Recent Research Advances in Double-Strand Break and Mismatch Repair Defects in Prostate Cancer and Potential Clinical Applications
by: Damian Jaworski, et al.
Published: (2023-05-01)

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy
by: Julie N. Graff, et al.
Published: (2020-08-01)

Comparing efficacy of first-line treatment of metastatic castration resistant prostate cancer: a network meta-analysis of randomized controlled trials
by: Yang Liu, et al.
Published: (2023-11-01)

Immune checkpoint inhibitors and prostate cancer: a new frontier?
by: Alessandra Modena, et al.
Published: (2016-04-01)

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review
by: Claire H. Li, et al.
Published: (2019-12-01)

Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer
by: Anna E. Harris, et al.
Published: (2022-10-01)

Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report
by: Taylor Ryan McFarland, et al.
Published: (2021-01-01)

Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs
by: Ferretti S, et al.
Published: (2023-06-01)

A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer
by: Zakaria Alameddine, et al.
Published: (2023-10-01)

Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs
by: Turco F, et al.
Published: (2022-09-01)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
by: Jacob J. Adashek, et al.
Published: (2019-08-01)

A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a <i>RAD51B Alteration</i>
by: Brieuc Sautois, et al.
Published: (2022-06-01)

Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?
by: Alessandro Sciarra, et al.
Published: (2023-08-01)

PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview
by: Islam Kourampi, et al.
Published: (2023-01-01)

Exceptional Response to Pembrolizumab in a Mismatch Repair-Deficient Aggressive Prostate Cancer with Somatic EPCAM, MSH2, and MSH6 Co-Deletion: A Case Report
by: Dennis Hoch, et al.
Published: (2023-11-01)

PARP inhibitors in metastatic prostate cancer
by: Amy K. Taylor, et al.
Published: (2023-04-01)